纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | DA |
Uniprot No | Q8TAP4 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-145aa |
氨基酸序列 | MLSVQPDTKP KGCAGCNRKI KDRYLLKALD KYWHEDCLKC ACCDCRLGEV GSTLYTKANL ILCRRDYLRL FGVTGNCAAC SKLIPAFEMV MRAKDNVYHL DCFACQLCNQ RFCVGDKFFL KNNMILCQTD YEEGLMKEGY APQVR |
预测分子量 | 16,5 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DA重组蛋白的示例参考文献(注:以下内容为模拟生成,实际文献请通过学术数据库查询):
---
1. **文献名称**: *Expression and Purification of Recombinant Dopamine D2 Receptor in E. coli*
**作者**: Zhang, L., et al.
**摘要**: 本研究报道了利用大肠杆菌表达系统高效表达人源多巴胺D2受体(DA-D2R)的重组蛋白。通过优化密码子及纯化步骤,获得了高纯度蛋白,为后续受体功能研究提供了材料基础。
---
2. **文献名称**: *Structural Insights into DA-binding Proteins via Cryo-EM*
**作者**: Thompson, R.J., & Kim, S.
**摘要**: 利用冷冻电镜技术解析了DA重组蛋白(DA-RP1)与配体的复合物三维结构,揭示了其特异性结合位点及构象变化机制,为靶向药物设计提供了结构依据。
---
3. **文献名称**: *Recombinant DA Protein Alleviates Parkinsonian Symptoms in Rodent Models*
**作者**: Gupta, A., et al.
**摘要**: 实验证明,重组表达的多巴胺能蛋白(DA-Protein X)可通过血脑屏障并在帕金森病模型小鼠中显著改善运动功能障碍,提示其潜在治疗价值。
---
4. **文献名称**: *Optimization of Yeast-based Production for DA Fusion Proteins*
**作者**: Müller, F., & Schmidt, H.
**摘要**: 通过改造毕赤酵母表达系统,实现了DA重组融合蛋白(DA-FP2)的高效分泌表达,产量较传统方法提升3倍,降低了工业化生产成本。
---
**提示**:实际研究中建议通过PubMed、Web of Science等平台,以关键词“recombinant dopamine protein”“DA receptor expression”等检索最新文献。
**Background of Recombinant Proteins**
Recombinant proteins are engineered molecules produced through genetic engineering techniques, enabling the synthesis of specific proteins by introducing exogenous DNA into host organisms. This technology emerged in the 1970s with advancements in molecular cloning, revolutionizing biotechnology by allowing large-scale production of proteins that are otherwise scarce or difficult to isolate from natural sources.
The process involves inserting a target gene into expression vectors (e.g., plasmids), which are then introduced into host cells such as *E. coli*, yeast, insect, or mammalian cells. These hosts utilize their cellular machinery to transcribe and translate the gene into the desired protein. Prokaryotic systems like *E. coli* are favored for simplicity and cost-effectiveness, while eukaryotic systems (e.g., CHO cells) are used for complex proteins requiring post-translational modifications (e.g., glycosylation).
Recombinant proteins have transformative applications across medicine, research, and industry. Therapeutically, they are pivotal in producing insulin, monoclonal antibodies, vaccines (e.g., hepatitis B), and cytokines (e.g., interferons). In research, they serve as tools for studying protein functions, drug screening, and structural biology. Industrially, they are used in enzymes for biofuels, food processing, and bioremediation.
Challenges include optimizing expression yields, ensuring proper protein folding, and minimizing host-induced modifications. Innovations like CRISPR-Cas9. cell-free systems, and synthetic biology continue to refine production efficiency and expand possibilities. Recombinant protein technology remains a cornerstone of modern biotechnology, driving advancements in personalized medicine, sustainable manufacturing, and scientific discovery.
在生物科技领域,蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者,凭借自身卓越的研发实力,每年能成功研发 1000 多种全新蛋白,在重组蛋白领域不断突破。 在重组蛋白生产过程中,艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白,到具有特定催化功能的酶、参与信号传导的激酶,再到用于免疫研究的病毒抗原,艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统,昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势,能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求,从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品,更是从源头到终端的一站式解决方案。从最初的基因合成,精准地构建出符合要求的基因序列,到载体构建,为蛋白表达创造适宜的环境,再到蛋白质表达和纯化,每一个环节都严格把控。我们充分尊重客户的个性化需求,在表达 / 纯化标签的选择、表达宿主的确定等方面,为客户量身定制专属方案。 同时,艾普蒂还配备了多种纯化体系,能够应对不同特性蛋白的纯化需求。这种灵活性和专业性,极大地提高了蛋白表达和纯化的成功率,让客户的研究项目得以顺利推进,在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台,包括: 哺乳动物细胞表达平台:利用哺乳动物细胞精准修饰蛋白,产出与天然蛋白相似的重组蛋白,用于药物研发、细胞治疗等。 杂交瘤开发平台:通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株,优化后的技术让抗体亲和力与特异性更高,应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台:FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞;Beacon® 基于微流控技术,单细胞水平捕获、分析 B 细胞,挖掘抗体多样性,缩短开发周期。 凭借这些平台,艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务,推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富,拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上,艾普蒂生物不仅经验老到,还积累了详实的成功案例。针对客户的工业化生产需求,我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节,对重组蛋白基因序列进行优化,全面探索多种条件,精准找出最契合客户需求的生产方法。 此外,公司还配备了自有下游验证平台,可对重组蛋白展开系统的质量检测与性能测试,涵盖蛋白互作检测、活性验证、内毒素验证等,全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发,确保生产出的蛋白质具备所需的纯度、稳定性与生物活性,这对于保障药物的安全性和有效性起着关键作用 ,与艾普蒂生物共同推动着行业的发展。
×